4"-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family

被引：3

作者：

Lobatón, E

Velázquez, S

San-Félix, A

De Clercq, E

Balzarini, J

Camarasa, MJ

机构：

[1] CSIC, Inst Quim Med, E-28006 Madrid, Spain

[2] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium

来源：

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2001年 / 20卷 / 4-7期

关键词：

D O I：

10.1081/NCN-100002357

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The first TSAO derivative that lacks the amino group at the 3'-spiro moiety has been prepared. This molecule retained its HIV-1 specificity (NNRTI characteristic) but did not select for any of the classical NNRTI-specific mutations in the NNRTI binding pocket, including 138-Lys (TSAO resistant strain).

引用

收藏

页码：711 / 714

页数：4

相关论文

共 15 条

[1] 2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-3'-SPIRO-5''-(4''-AMINO-1',2''-OXATHIOLE-2'',2''-DIOXIDE)PYRIMIDINE (TSAO) NUCLEOSIDE ANALOGS - HIGHLY SELECTIVE INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 THAT ARE TARGETED AT THE VIRAL REVERSE-TRANSCRIPTASE [J].

BALZARINI, J ;

PEREZPEREZ, MJ ;

SANFELIX, A ;

SCHOLS, D ;

PERNO, CF ;

VANDAMME, AM ;

CAMARASA, MJ ;

DECLERCQ, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4392-4396

[2]

Balzarini Jan, 1993, Drugs of the Future, V18, P1043

[3] TSAO DERIVATIVES - HIGHLY SPECIFIC INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) REPLICATION [J].

CAMARASA, MJ ;

PEREZPEREZ, MJ ;

VELAZQUEZ, S ;

SANFELIX, A ;

ALVAREZ, R ;

INGATE, S ;

JIMENO, ML ;

KARLSSON, A ;

DECLERCQ, E ;

BALZARINI, J .

NUCLEOSIDES & NUCLEOTIDES, 1995, 14 (3-5) :585-594

[4] 3'-SPIRO NUCLEOSIDES, A NEW CLASS OF SPECIFIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INHIBITORS - SYNTHESIS AND ANTIVIRAL ACTIVITY OF [2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-BETA-D-XYLO AND RIBOFURANOSE]-3'-SPIRO-5''-[4''-AMINO-1'',2''-OXATHIOLE 2'',2''-DIOXIDE] (TSAO) PYRIMIDINE NUCLEOSIDES [J].

CAMARASA, MJ ;

PEREZPEREZ, MJ ;

SANFELIX, A ;

BALZARINI, J ;

DECLERCQ, E .

JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (15) :2721-2727

[5] HIV-1 specific reverse transcriptase inhibitors:: Why are TSAO-nucleosides so unique? [J].

Camarasa, MJ ;

San-Félix, A ;

Pérez-Pérez, MJ ;

Velázquez, S ;

Alvarez, R ;

Chamorro, C ;

Jimeno, ML ;

Pérez, C ;

Gago, F ;

De Clercq, E ;

Balzarini, J .

JOURNAL OF CARBOHYDRATE CHEMISTRY, 2000, 19 (4-5) :451-469

[6] The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection [J].

De Clercq, E .

ANTIVIRAL RESEARCH, 1998, 38 (03) :153-179

[7] TOWARD IMPROVED ANTI-HIV CHEMOTHERAPY - THERAPEUTIC STRATEGIES FOR INTERVENTION WITH HIV-INFECTIONS [J].

DECLERCQ, E .

JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (14) :2491-2517

[8] The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer [J].

Harris, D ;

Lee, R ;

Misra, HS ;

Pandey, PK ;

Pandey, VN .

BIOCHEMISTRY, 1998, 37 (17) :5903-5908

[9] RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION [J].

HO, DD ;

NEUMANN, AU ;

PERELSON, AS ;

CHEN, W ;

LEONARD, JM ;

MARKOWITZ, M .

NATURE, 1995, 373 (6510) :123-126

[10]

JONCKHEERE H, 1994, J BIOL CHEM, V269, P25255